Description
Encorat (valproic acid) Tablets 200 mg. №30
Composition
Active Ingredient: Valproic acid 200 mg per tablet.
Mechanism of Action
Pharmacological Properties: Valproic acid works by increasing the levels of gamma-aminobutyric acid (GABA) in the brain, which has inhibitory effects, helping to control seizures and stabilize mood in bipolar disorder.
Indications for Use
Indicated for: Treatment of epilepsy, bipolar disorder, and migraine headaches.
Contraindications
Do not use if: Allergic to valproic acid, liver disease, urea cycle disorders.
Side Effects
Common side effects may include nausea, dizziness, drowsiness, and weight gain. Serious side effects such as liver problems and pancreatitis may occur in rare cases.
Usage Instructions
Administration: Take with food to reduce stomach upset. Swallow the tablet whole, do not crush or chew.
Dosage: The usual starting dose is 10-15 mg/kg/day, gradually increasing to achieve the desired clinical response.
Benefits Compared to Analogues
Valproic acid has shown superior efficacy in managing seizures and stabilizing mood compared to other antiepileptic drugs and mood stabilizers.
Suitable Patient Groups
Valproic acid is suitable for both adult and pediatric patients with epilepsy and bipolar disorder. However, caution is advised in the elderly population due to an increased risk of adverse effects.
Storage and Shelf Life
Store at room temperature away from moisture and heat. Keep out of reach of children. Check the expiration date on the packaging and do not use after the stated expiration date.
Packaging Description
The product is available in blister packs containing 30 tablets of 200 mg each. The packaging is designed to ensure the stability and integrity of the tablets.
Clinical Evidence and Proven Effectiveness
Valproic acid has been extensively studied for its efficacy in managing various neurological disorders. Research published in the Journal of Clinical Psychopharmacology demonstrated the effectiveness of valproic acid in controlling manic episodes in patients with bipolar disorder. Additionally, a study in the Journal of Neurology, Neurosurgery & Psychiatry highlighted the role of valproic acid in reducing the frequency and severity of migraine headaches.
Clinical trials have shown that valproic acid is effective in reducing the frequency and severity of seizures in patients with epilepsy. A study published in Epilepsia demonstrated a significant reduction in seizure frequency with valproic acid compared to a placebo group.
